Form 8-K - Current report:
SEC Accession No. 0001213900-21-063775
Filing Date
2021-12-07
Accepted
2021-12-07 06:41:45
Documents
16
Period of Report
2021-12-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea151838-8k_aditxtinc.htm   iXBRL 8-K 30810
2 UNDERWRITING AGREEMENT BETWEEN THE COMPANY AND DAWSON JAMES SECURITIES, INC., DA ea151838ex1-1_aditxtinc.htm EX-1.1 197520
3 SHEPPARD, MULLIN, RICHTER & HAMPTON LLP LEGAL OPINION ea151838ex5-1_aditxtinc.htm EX-5.1 18799
4 PRESS RELEASE DATED DECEMBER 6, 2021 ea151838ex99-1_aditxtinc.htm EX-99.1 8082
5 GRAPHIC ex5-1_001.jpg GRAPHIC 3273
  Complete submission text file 0001213900-21-063775.txt   496277

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE adtx-20211201.xsd EX-101.SCH 3019
7 XBRL LABEL FILE adtx-20211201_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE adtx-20211201_pre.xml EX-101.PRE 22355
9 EXTRACTED XBRL INSTANCE DOCUMENT ea151838-8k_aditxtinc_htm.xml XML 3695
Mailing Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219
Business Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219 909-488-0844
Aditxt, Inc. (Filer) CIK: 0001726711 (see all company filings)

EIN.: 823204328 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39336 | Film No.: 211474648
SIC: 2834 Pharmaceutical Preparations